KEY POINTS
- This preclinical study investigated the role of platelet-derived transforming growth factor β1 (TGFβ1) in radiation-induced cardiac fibrosis using wild-type mice and PF4Cre;Tgfb1fl/fl mice with targeted TGFβ1 depletion in platelets and megakaryocytes. Thoracic irradiation consisted of either 16 Gy in one fraction or 20 Gy in five daily 4-Gy fractions, with cardiac pathology and function evaluated over 4–20 weeks. Human platelet and monocyte experiments, together with plasma samples from lung cancer patients, supplemented the animal findings.
- Thoracic irradiation produced progressive myocardial fibrosis in wild-type animals. Following single-fraction 16-Gy irradiation, cardiac fibrosis was approximately fivefold higher than in sham-irradiated controls by four weeks, increasing further over subsequent observations (p<0.01). By contrast, platelet-TGFβ1-deficient mice exhibited substantially less myocardial collagen deposition, with fibrosis levels approaching those of unirradiated controls. A similar protective pattern was observed after fractionated thoracic irradiation.
- Reduced cardiac fibrosis was accompanied by preservation of diastolic function. Irradiated wild-type mice developed elevated left ventricular E/A ratios >2, consistent with impaired ventricular filling, while platelet-TGFβ1-deficient mice retained ratios around 1–1.5. Left ventricular ejection fraction remained preserved, resembling an early heart-failure-with-preserved-ejection-fraction phenotype. These findings provide functional support for the histological changes but do not represent a validated clinical HFpEF model.
- Platelet-derived TGFβ1 was linked to radiation-associated profibrotic signaling. Circulating total TGFβ1 approximately doubled after irradiation in wild-type animals but did not increase similarly in platelet-TGFβ1-deficient mice. Myocardial phosphorylated Smad2, reflecting downstream TGFβ signaling, increased approximately twofold after irradiation (p=0.013) and was significantly lower in TGFβ1-deficient animals (p=0.04). Irradiated wild-type hearts also showed increased inflammatory and profibrotic macrophage populations.
- Complementary experiments identified potential mechanisms linking platelet activation and cardiac inflammation. Platelet-derived TGFβ1 promoted human monocyte migration in vitro, an effect inhibited by an anti-TGFβ1 antibody. Ionizing radiation increased activation of latent TGFβ1 in platelet releasates (p=0.045), with additional enhancement under reactive oxygen species-generating conditions. These findings support a pathway involving ROS-dependent TGFβ1 activation, immune-cell recruitment, and collagen deposition.
- A small human translational analysis showed increased circulating active TGFβ1 after thoracic RT. Among 20 patients with NSCLC, 17 (85%) demonstrated higher active plasma TGFβ1 levels 3–6 weeks after radiotherapy than at baseline. However, the human component did not establish an association with subsequent cardiac fibrosis, diastolic dysfunction, or clinical cardiovascular events. The human results therefore provide preliminary biological consistency rather than confirmation of the proposed mechanism in patients.
- Clinical translation remains uncertain. The mouse irradiation regimens and exposure geometry differ from contemporary partial-heart doses during thoracic cancer treatment. Genetic platelet-specific TGFβ1 deletion is also not equivalent to a clinically available targeted intervention, and the effects of sustained pathway suppression on immunity, wound repair, and normal cardiovascular function were not tested. No pharmacological prevention or reversal of established radiation-induced cardiac disease was demonstrated.
CLINICAL TAKEAWAY
Platelet-derived TGFβ1 appears to contribute to radiation-associated myocardial fibrosis and diastolic dysfunction in experimental models, suggesting that selective modulation of this pathway may offer a future cardioprotective strategy. The findings are strengthened by complementary genetic, cellular, and limited human plasma observations. However, they do not establish a clinical biomarker or justify TGFβ-targeted prevention in patients undergoing thoracic radiotherapy.